ALLGF News and Press, Alligator Bioscience AB From 03/18/19

LUND, Sweden , March 18, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) , today announce that they will present preclinical data for the drug candidate ATOR-1017 at the 4th Annual Immuno-oncology Summit Europe, to be held in London on March 18-22, 2019 . ATOR-...

LUND, Sweden , March 7, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the first patient has successfully been dosed in its phase I study of ATOR-1015, its drug candidate in development for tumor-directed immunotherapy. ATOR-1015 is designed wit...

Alligator Bioscience ( OTC:ALLGF ): Q4 GAAP EPS of -SEK0.43. More news on: ALLIGATOR BIOSCIENCE AB, Earnings news and commentary, , Read more ...

STOCKHOLM , Feb. 14, 2019 /PRNewswire/ -- Significant events October-December The Swedish MPA (Medical Products Agency) approved start of Phase I clinical trial of ATOR-1015. New preclinical data for ATOR-1017 and ALG.APV-527 presented at the Annual Meeting of the Soci...

First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies LUND, Sweden , Jan. 29, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), announces the publication of the results from a clinical phase ...